Global Fund For Antimicrobial Resistance Proposed, Financing Unclear
This article was originally published in The Pink Sheet Daily
The U.K.’s Review on Antimicrobial Resistance, led by leading health economist Jim O’Neill, has come up with initial proposals to tackle the problem, with final conclusions expected in the summer of 2016.
You may also be interested in...
New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.
The firm is developing a novel class of antibacterials that could enable shelved agents for Gram-positive infections to reach and kill Gram-negative bacteria.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.